O áudio deste episódio pode não estar acessível.
How to fix it?
SOBRE ESTE EPISÓDIO
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Inglês
Estados Unidos da América
PESQUISAR EPISÓDIOS PASSADOS
Pesquisar episódios anteriores de FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
OUTROS EPISÓDIOS NESTE PODCAST
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Aviso: O podcast e a arte incorporada nesta página são de U.S. Food and Drug Administration, Center for Drug Evaluation and Research, que é propriedade de seu proprietário e não é afiliado ou endossado por Listen Notes, Inc.
EDITAR
Obrigado por ajudar a manter a base de dados dos podcasts atualizada.
